Apr 30, 2024 8:30am EDT Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Apr 25, 2024 8:30am EDT Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
Mar 12, 2024 8:00am EDT Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Feb 27, 2024 7:15pm EST Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Feb 20, 2024 8:30am EST Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Feb 06, 2024 8:30am EST Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs